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Positron Emission TomographyIntroduction: Neuritic amyloid plaques and neuroﬁbrillary tangles, the hallmark pathologic lesions of Alzheimer's
disease, are thought to develop before the symptoms of brain failure are clinically detectable. Imagingmethods ca-
pable of detecting the presence of neuritic amyloid plaques should improve a clinician's ability to identify
Alzheimer's disease during the earliest symptomatic phase and to identify at-risk individuals presymptomatically.
Currently the best studied amyloid imaging ligand is [11C]Pittsburgh Compound B ([11C]PiB). However, the 20-
minute half-life of this radiotracer limits its use. This study is designed to evaluate the performance characteristics
of [18F]ﬂutemetamol and to independently compare results to [11C]PiB in the same subjects.
Methods: Twenty-three subjects, 15 cognitively normal (NL) and 8with a clinical diagnosis of Alzheimer's Demen-
tia (AD), underwent [11C]PiB and [18F]ﬂutemetamol PET scans within 28 days of study enrollment. We studied
both normal andAD subjects to assess the uptake characteristics across a range of amyloid positivity. Blinded visual
reads were conducted by ﬁve raters. Correlation analyses were performed between cortical SUVR for the two
tracers and also between rater scores and SUVR for each tracer. Overall reader accuracy for classifying scans as am-
yloid positive or negative was determined for each tracer using SUVR classiﬁcation as the standard.
Results: The linear correlation coefﬁcient betweenglobal cortical SUVR for the two tracerswasR2=0.85, indicating
that both tracers have similar retention characteristics. The two tracers were well correlated for rater-determined
AD-like positivity (Cohen κ=0.82). Averaged visual ratings and global cortical SUVR disagreed on their classiﬁca-
tion in 2/23 [11C]PiB scans and 4/23 [18F]ﬂutemetamol scans.
Conclusions: [11C]PiB and [18F]ﬂutemetamol have similar retention characteristics across a range of amyloid nega-
tive to positive subjects. Both tracers performed similarly when a standardized visual read technique was used to
classify scans as amyloid-positive or amyloid-negative and correlated well with SUVR classiﬁcations. However,
care in visual interpretation of amyloid positive versus amyloid negative regions should be taken, particularly in
the case of [18F]ﬂutemetamol when considering cortical vs. white-matter retention.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Alzheimer's dementia (AD) is the most common form of dementia in
the elderly, affecting more than 4 million people in the United States.
Although the etiology of AD has not been deﬁnitively established, con-
verging evidence suggests that the Aβ peptide may play an important
role in the pathogenesis of the disease. Accumulation of Aβ ﬁbrils in theine, Department of Radiology,
et, Pittsburgh, PA 15213, USA.
. This is an open access article underform of amyloid plaques is one of the hallmarks of the disease and is a
key component of the neuropathological criteria for autopsy-based con-
ﬁrmation of diagnosis (Hyman and Trojanowski, 1997;Mirra et al., 1991).
Imaging techniques utilizing radiolabeled positron emission tomog-
raphy (PET) tracers that bind to the aggregated Aβ peptides in amyloid
plaques have the potential to directly assess relative brain amyloid
plaque pathology. The importance of PET with Pittsburgh Compound-
B, N-methyl-[11C]2-(4′-methylaminophenyl)-6-hydroxybenzothiazole
(also known as [11C]PiB) as a research tool iswell established. Neverthe-
less, the short half-life (20min) of the 11C radiolabel limits its utility as a
tool for community-based diagnostic screening and therapeuticthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Study subject demographics.
Normal Alzheimer's
Number of subjects 15 8
Age (years)
Mean (SD) 71 (8.49) 75 (10)
Median 68 75
Min 59 57
Max 84 87
Gender, n (%)
Male 5 (33) 4 (50)
Female 10 (67) 4 (50)
Race, n (%)
Black or African American 1 (7) 1 (12.5)
White 14 (93) 7 (87.5)
MMSE Score
Mean (SD) 29 (0.91) 21 (4.37)
Median 30 21
Min 27 16
Max 30 27
Global CDR, n (%)
0.0—No impairment 14 (93.3) 0
0.5—Questionable impairment 1 (6.7) 2 (25)
1.0—Mild-impairment 0 5 (62.5)
2.0—Moderate impairment 0 1 (12.5)
3.0—Severe impairment 0 0
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an 18F-labeled tracerwith kinetics similar to those of [11C]PiB. The radio-
logical half-life (109 min) of such a tracer would allow its distribution
from centralized production facilities as in the case of 18F-labeled
ﬂuorodeoxyglucose (FDG), which is now in widespread use in
community-based clinics.
The present study is designed to compare the imaging characteris-
tics of a novel 18F-labeled amyloid ligand, [18F]ﬂutemetamol, to those
of [11C]PiB in the same subjects, across a range of brain amyloid accumu-
lation. The performance of a visual read technique for both tracers was
also evaluated by comparison to quantitative measures. A brief back-
ground of these two tracers is provided below.
The PET radiotracer [11C]PiB has been developed for in vivo imag-
ing of amyloid plaque (Klunk et al., 2004;Mathis et al., 2003). Studies
have shown that [11C]PiB retention in AD subjects is substantially
higher than that of controls in speciﬁc cortical areas subject to AD-
related Aβ accumulation but is similar in areaswithout Aβ deposition
(e.g., subcortical whitematter, cerebellum). Subjects with a diagnosis of
mild cognitive impairment (MCI) exhibit [11C]PiB retention spanning
both the control and AD retention levels (Engler et al., 2004, 2006;
Head et al., 2012; Kemppainen et al., 2007; Klunk et al., 2004; Pike
et al., 2007a; Rowe et al., 2007).
A recently developed 18F-labeled amyloid binding radiotracer struc-
turally related to [11C]PiB that has been proposed as an amyloid imaging
agent is [18F]ﬂutemetamol. A phase 2 study has shown (Vandenberghe
et al., 2010) that [18F]ﬂutemetamol selectively labels Aβ plaques in a
manner similar to [11C]PiB.
2. Materials and methods
2.1. Subjects
Subjects from the University of Pittsburgh Alzheimer's Disease Center
longitudinal study cohort between55 and90 years of agewere eligible for
this study. All participants signed University of Pittsburgh IRB approved
informed consent. Clinical cognitive assessment, including standardized
measures of cognition, behavior, and function, described by National
Alzheimer's Coordinating Center (NACC) Uniform Data Set, version 2.0,
served as the basis for study enrollment and cohort assignment.
Testing and clinical dementia rating assessment was completed
within three months prior to enrollment. Eligibility requirements for
enrollment in the normal (NL) cohort included: Mini Mental State
(MMS) score between 27 and 30; clinical dementia rating (CDR) score
of 0; and cognitive impairment scores of no less than 1 standard devia-
tion below the established age- and education-adjusted means for the
ADC–NACC Uniform Cognitive Assessment Battery. Eligibility require-
ments for enrollment in the probable AD (AD) cohort included: MMS
scores between 16 and 27; CDR score ≥0.5; and probable Alzheimer's
disease based on NINCDS–ADRDA criteria.
At the time of subject enrollment, demographic information was re-
corded and a complete medical history and physical examination was
performed. Patients with contraindications for MRI, e.g., those with an-
eurysm clips or metal fragments in the body were excluded. Subjects
with signiﬁcant neurologic disease, such as cerebral infarctions, history
of signiﬁcant head trauma or MRI brain scans showing evidence of
clinically meaningful abnormalities as well as subjects with psychiatric
disorders including serious major depression, history of schizophrenia,
or history of substance abuse (DSM-IV criteria) were also excluded. A
total of 8 patients with a clinical diagnosis of probable Alzheimer's dis-
ease and 15 cognitively normal elderly subjects were recruited into
the study from March 10, 2009 to September 30, 2010. Participants in
the normal cohort had mean age 71 years (range 59 to 84), whereas
the Alzheimer's cohort had mean age 75 years (range 57 to 87). Partic-
ipants in the normal cohort had mean MMS score 29 (range 27 to 30),
compared with the Alzheimer's cohort, with mean score 21 (range 16
to 27). Subject demographics are listed in Table 1.As stated in the Introduction, the goal of this study is to compare im-
aging characteristics of two amyloid tracers. It is not aimed at evaluating
tracer efﬁcacy for identifying patients with clinically diagnosable AD.
For the purpose of achieving our goal, it was desirable that our subjects
exhibit a range of amyloid load. To help achieve this, a subset (n= 6) of
NL subjects were selected to participate in this study based on the re-
sults of a prior positive PiB scan.
2.2. Radiotracer production
The full radiosyntheses of [11C]PiB (Wilson et al., 2004) and
[18F]ﬂutemetamol (Mason et al., 2009) are described elsewhere.
2.3. Imaging protocol
The Alzheimer's Disease Neuro-Initiative (ADNI) MRI protocol
(3D rapid gradient echo (MP-RAGE) and an axial proton density
scan) was performed prior to the PET imaging procedure (Jack
et al., 2008). If an ADNIMRI had been performedwithin the 6months
prior to enrollment, it was not repeated. Each participant underwent
two PET scanning sessions, one using the [11C]PiB tracer and another
using [18F]ﬂutemetamol. Both PET scans were completed within 29
days of subject enrollment.
Due to the relatively short half-life of 11C, in caseswhere the 11C trac-
er was injected ﬁrst, it was possible for subjects to receive both scans on
the same day. In such cases (7 of 8 AD and 11 of 15 NL) a minimum
elapsed time of 2 h (six 11C half-lives) was required between [11C]PiB
and [18F]ﬂutemetamol injections.
The remaining 5 subjects had the two scans on different days. One
NL subject had the [18F]ﬂutemetamol scan 28 days before the [11C]PIB
scan. The other 3 NL and 1 AD subject had their [11C]PIB scans ﬁrst
(scan separation of 7, 6, and 7 days for NL and 29 days for AD).
Under the [11C]PiB protocol, subjects were injected with 15 ±
1.5 mCi of tracer administered over a 20-second period. PET scanning
commenced 50 min after injection and data were acquired for 20 min
in 4 frames, each of 5min duration (i.e., 50–70min post-injection scan).
Under the [18F]ﬂutemetamol protocol, subjects were injected with
10 mCi of tracer and scanning commenced 90 min after injection. Data
were acquired for 30 min using six 5-minute frames (i.e., 90–120 min
594 J.M. Mountz et al. / NeuroImage: Clinical 9 (2015) 592–598post-injection scan). In each case, prior to the emission scan, 10 min of
transmission data, required for attenuation and scatter correction,
were acquired. All PET data were acquired on a Siemens/CTI ECAT
HR+ BGO scanner operating in 3-D mode (axial ﬁeld-of-view:
15.5 cm; 63 planes).2.4. Image processing
Acquired PET data were reconstructed into a 128 × 128 × 63
(axial) matrix with voxel dimensions of 0.21 × 0.21 × 0.24 cm. Re-
construction was performed using manufacturer supplied software
and included corrections for attenuation, scatter, random coinci-
dences and dead time. Images for regional analysis were processed
using Fourier rebinning (FORE) followed by direct Fourier recon-
struction. Images were smoothed with a 3 mmHann ﬁlter. Following
reconstruction, image sets were inspected and, if necessary,
corrected for inter-frame motion. Each subject's [11C]PiB and [-
18F]ﬂutemetamol scans were separately registered to the subject's
AC–PC oriented MR scan using an Automated Image Registration
(AIR) technique (Woods et al., 1993). A summation over the time
frames was performed to produce a single time-frame image, i.e., a
50–70 min [11C]PiB image and a 90–120 min [18F]ﬂutemetamol image
for each subject.
Images for the visual reads were produced by ﬁrst summing the
sinograms over the time frames, followed by FORE rebinning and then
reconstruction using OSEM with 4 iterations of 16 subsets. Although
subject MR scans were not used for the visual reads, the PET scans
were registered to MR scans as described above for the purpose of
bringing them into uniform AC–PC alignment. No smoothing was ap-
plied to these images, however, in each case a new image was formed
by summing adjacent axial planes resulting in a ﬁnal axial plane thick-
ness of 0.48 cm (2 × 0.24 cm).2.5. Data analysis
2.5.1. Identiﬁcation of brain regions for analysis
Five cortical brain sub-regions known to accumulate amyloid
plaques in AD were selected for tracer retention analysis: anterior cin-
gulate; precuneus; frontal cortex; parietal cortex; and lateral temporal
cortex.
To investigate potential differences in nonspeciﬁc retention between
[11C]PiB and [18F]ﬂutemetamol the pons region was also analyzed. The
pons is generally spared from amyloid plaque accumulation and this
white-matter rich area has substantial nonspeciﬁc signal (Price et al.,
2005).
Region-of-interest (ROI) boundaries were manually-deﬁned using
the structural MRI for anatomical reference and criteria that have prov-
en to provide highly reproducible outcomes (Rosario et al., 2011). The
Rosario et al. publication also shows examples of regional delineations
on MRI scan section (as shown in Fig. 1).Fig. 1. Image example of the ROIs provided to visual raters. The 5 brain regions (10 total ROI)
considered as a bilaterally symmetric pattern of positivity in the frontal, parietal and temporal2.5.2. Regional analysis
A normalized regional analysis was performed in which the cerebel-
lar cortex was designated as the reference region for nondisplaceable
(i.e., free and nonspeciﬁc) retention. Mean concentrations for the re-
gions described above were obtained for all subjects and both tracers.
Normalized regional retention values (SUVR) were produced by divid-
ing each regional concentration by the concentration within the cere-
bellum ROI from the same image. An overall global cortical SUVR
value was determined by averaging the SUVR values from the 5 cortical
subregions.
2.5.3. Visual analysis
A standard visual analysis procedure, outlined in the following sub-
sections, was established at a reader protocol/training meeting at the
University of Pittsburgh. The protocol was developed using a set of
[11C]PIB and [18F]ﬂutemetamol images from amyloid-positive and
amyloid-negative subjects. Otherwise, the training scans were not in-
cluded in the study reported herein.
2.5.3.1. Overview. Study scans were independently evaluated by ﬁve
raters (JMM, WEK, ADC, EM, HJA; all experienced neuroimaging re-
searchers). Raters were blinded to subject identity and diagnosis; sepa-
rate identiﬁers were used for the [11C]PIB and [18F]ﬂutemetamol
studies, preventing cross identiﬁcation of scans. Raters ﬁrst evaluated
the PiB scans followed by Flutemetamol scans. At any given time,
scans from only the tracer under evaluation were available to readers,
i.e. during [11C]PIB evaluation, [18F]ﬂutemetamol scans were inaccessi-
ble and vice versa.
Following initial read completion, the ﬁve raters met as a group for a
consensus read. Two separate sessions were held; one for [11C]PIB and
one for [18F]ﬂutemetamol. In any case with less than 100% agreement
in the individual ratings, the scans were projected for simultaneous
viewing, and an attempt was made to arrive at a consensus opinion.
The predetermined consensus rules were that if at least four of the
raters agreed after the discussion, a consensus rating was generated,
otherwise, the case would be scored “no consensus.” We note here
that a consensus was arrived at in all cases.
2.5.3.2. Image presentation. Before commencement of the visual reads,
the readers agreed that images would initially be displayed using a con-
tinuous colormap, without visual breaks. Thus images were displayed
using a reader adjustable HotMetal color schemewith the scale initially
spanning the full image intensity range.
While the reader was free to view any slice or to use an orthogonal
viewing tool, the following minimal procedure was used. All slices
wereﬁrst simultaneously observed on a single display page for evidence
of obvious positive signal. Following this, the following axial slices were
examined in an enlarged, single slice format: (1) a slice at the ﬁrst ap-
pearance of lateral ventricles (going from superior to inferior) and
(2) every axial slice until the cerebellar peduncles were reached.
Seven consecutive sagittal slices centered at the midline were also
reviewed.indicated are those generally attributed to be the typical AD pattern, which is generally
cortices, anterior cingulate and precuneus.
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following 3 evaluations in the order speciﬁed. In these descriptions, “pos-
itivity” is deﬁned to be gray matter signal greater than or equal to signal
in white matter regions such as pons, cerebellar peduncles, and subcor-
tical white matter. Except for the guidancematerial provided for evalua-
tion #3, described below, the visual ratings were performed using the
PET scans only, i.e., without reference to subjects' MRI or other anatom-
ical images. Visual classiﬁcation examples are shown in Fig. 2.
1) Any-Region Positivity: a statement of certainty as to whether the
scan was amyloid-positive in any gray matter area. This reading
was not limited to the ﬁve graymatter areas listed below. Score def-
initions were: 1 = deﬁnitely negative; 2 = probably negative; 3 =
probably positive; 4 = deﬁnitely positive.
2) AD-like Positivity: a statement of certainty as to whether the typical
AD regional pattern was present (same numerical ratings as above).
The typical AD pattern was considered a generally bilaterally sym-
metric pattern of positivity in the frontal, parietal and temporal cor-
tices, anterior cingulate and precuneus. Cases were allowed to be
frontally predominant or posteriorly predominant, but cases that
were only positive in focal areas (e.g., unilateral occipital pole)
were to be rated “2 = probably negative” from this “AD-like” per-
spective. Readers were instructed that this AD-like score could be
lower than the “Any-Region” score, but could never be higher.
3) Individual Region Positivity: because visual reads were to be corre-
lated to the normalized regional retention values, scans were visual-
ly evaluated with reference to the same ROIs as were used for the
quantitative analyses. To this end, readers were provided with a
hard copy depiction of orthogonal views of example ROIs overlaid
on a typical MRI (Fig. 1). Each of the 10 individual regions (frontal,
parietal, temporal cortices, anterior cingulate and precuneus; right
and left separately) were scored (rater regional score) using the
same 1–4 scale described above. A ﬁve-region average score (rater
regional average) was calculated as the simple arithmetic mean of
the 10 unilateral ROI scores and was correlated to the global cortical
SUVR.
2.5.4. Statistical analyses
In parts of this and the following sections, threshold values for global
cortical SUVR are used to classify scans as amyloid positive or negative,Fig. 2. Examples of [11C]PiB and [18F] ﬂutemetamol scans. The top row shows [11C]PiB images th
The bottom row shows these classiﬁcations for [18F]ﬂutemetamol. The arrows indicate the ba
classiﬁcations.i.e. PiB(+), PiB(−). For [11C]PiB, the threshold (1.51)was established in
a separate study (Cohen et al., 2013) using an objective sparse K-means
(SKM) with tight clustering approach. For the purposes of the current
study, the corresponding [18F]ﬂutemetamol threshold (1.66) was ob-
tained by transforming the PiB threshold using the global cortical
SUVR correlation parameters determined in the “Correlation of
[11C]PiB and [18 F]ﬂutemetamol SUVR within Subjects” analysis de-
scribed below (Section 3.1.1).
2.5.4.1. Correlation of [11C]PiB and [18 F]ﬂutemetamol SUVR within sub-
jects. Spearman's correlation coefﬁcients (r) were used to determine
the correlation between the [18F]ﬂutemetamol and [11C]PiB SUVR
values for each of the ﬁve cortical sub-regions as well as for the global
cortical retention value (i.e., the 5-subregion average) within subjects.
Similar correlation coefﬁcients were also calculated for pons SUVR.
2.5.4.2. Agreement between raters and tracers. Agreement between all 5
raters was determined by Fleiss' kappa (Fleiss, 1971) and was also
expressed as overall agreement as well as agreement across all cases
(Cicchetti and Feinstein, 1990; Spitzer and Fleiss, 1974).
Agreement between the two tracers for rater evaluation of any-
region positivity (concensus) and separately for AD-like positivity was
quantiﬁed using Cohen's kappa (Cohen, 1960).
2.5.4.3. Correlation of rater regional average to global SUVR.Global cortical
(5-subregion average) SUVR was compared to the rater regional-
average averaged across raters (i.e. rater regional scores, ranging from
1 to 4, averaged across 10 regions and 5 raters). Results are expressed
both graphically and numerically (by Spearman's correlation coefﬁ-
cient, r), for each tracer separately.
2.5.4.4. Correlation of rater regional score to regional SUVR. SUVR values
for each of the 10 cortical regions were compared to the averaged
(across raters) rater regional scores of each of the 10 regions described
above for both of the tracers. Results were expressed in terms of linear
correlation coefﬁcients.
2.5.4.5. Agreement between visual classiﬁcation and quantitative based
classiﬁcation of amyloid-positivity. An overall comparison of visual ﬁnd-
ing of amyloid positivity versus SUVR classiﬁcation of amyloid positivityat are classiﬁed as (left-to-right) “Negative”, “Any-region positive”, and “AD-like positive.”
sis for the “Any-region positive” positivity (in this case, right posterior temporoparietal)
Fig. 3. Plot of the [18F]ﬂutemetamol global SUVR versus [11C]PiB global SUVR values for NL
and AD subjects (N = 23). Triangles indicate AD subjects and circles indicate NL subjects.
Blue lines indicate the positivity thresholds for [11C]PiB (vertical) and [18F]ﬂutemetemol.
The six circles to the right of the vertical blue line are the PiB positive NL subjects.
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itivitywas 3 or greaterwere classiﬁed as amyloid positive by visual read,
otherwise images were classiﬁed as amyloid negative by visual read.
The global SUVR thresholds described in Section 2.5.4 were used to fur-
ther classify each image as amyloid positive or negative by SUVR. For
each tracer separately, agreement between visual and SUVR classiﬁca-
tion was expressed in terms of Cohen's kappa and percent agreement.
The SUVR threshold for amyloid positivity was 1.51 for [12C]PiB and
1.66 for [18F]ﬂutemetamol (see Section 2.5.4).
3. Results
3.1. Correlation of [11C]PiB and [18F]ﬂutemetamol SUVR within subjects
SUVR between the two tracers were compared as described in
Section 2.5.4.1. Results for cortical regions are reported in the sub-
section 3.1.1. Sub-section 3.1.2 describes the results for the pons and
cerebellum.
3.1.1. Cortical regions
Table 2 compares the uptake distribution, as measured by regional
SUVR, of [18F]ﬂutemetamol and [11C]PiB retentionwithin the same sub-
jects for both NL and AD subjects. The Spearman's correlation coefﬁ-
cients were high between [18F]ﬂutemetamol and [11C]PiB SUVR levels
for all ﬁve cortical sub-regions (0.89 or higher) as well as globally.
Fig. 3 shows [18F]ﬂutemetamol versus [11C]PiB global cortical SUVR for
all subjects. A high degree of linear correlation between the two tracers
was found; linear regression (y= 0.80× + 0.45, R2 = 0.85) indicated
that both tracers have similar retention characteristics. The slope of
0.8 indicates that the dynamic range for [18F]ﬂutemetamol is lower
that [11C]PiB. The lower SUVR range of [18F]ﬂutemetamol resulted
from the combination of both higher global region cortical SUV in the
amyloid-positive [11C]PIB subjects relative to that for [18F]ﬂutemetamol
(n = 12: [18F]ﬂutemetamol, 1.00 ± 0.24; [11C]PIB, 1.17 ± 0.36; P =
0.003 paired t-test, P = 0.219 Wilcoxon signed-rank test) and the
slightly lower cortical gray matter global region SUV in the amyloid-
negative [11C]PIB subjects relative to that for [18F]ﬂutemetamol.
3.1.2. Pons and cerebellum
The pons SUVR showed no difference between normal elderly and
AD subjects for either tracer (P = 0.96 for [18F]ﬂutemetamol and P =
0.73 for [11C]PiB, both by t-test). However, the pons SUVR was greater
for [18F]ﬂutemetamol, relative to [11C]PiB for both NL and AD subjects
(P b 0.0001 by paired t-test).
Related to its use as a potential reference region, the average
[18F]ﬂutemetamol SUV in pons for all subjects in this study was signif-
icantly higher than for [11C]PiB (n = 23: [18F]ﬂutemetamol = 1.44 ±
0.32; [11C]PiB = 1.16 ± 0.22; P b 0.0001 paired t-test, P = 0.003
Wilcoxon signed-rank test).
This was not the case for the cerebellar cortex reference region
where the average [18F]ﬂutemetamol SUV was slightly less than that
for [11C]PiB (n = 23: [18F]ﬂutemetamol = 0.53 ± 0.11; [11C]PiB =
0.59 ± 0.10; P = 0.002 paired t-test, P = 0.055 Wilcoxon signed-rank
test).Table 2
Spearman's correlation coefﬁcients for [18F]ﬂutemetamol and [11C]PiB SUVR levels for all
ﬁve cortical sub-regions.
Cortical region Spearman's correlation
Anterior cingulate 0.92 (b0.0001)
Posterior cingulate/precuneus 0.89 (b0.0001)
Frontal cortex 0.89 (b0.0001)
Parietal cortex 0.89 (b0.0001)
Lateral temporal cortex 0.89 (b0.0001)
Global cortical region 0.90 (b0.0001)
Pons 0.61 (b0.001)3.2. Agreement between raters and tracers
Agreement between the raters was determined as described in
Section 2.5.4.2. Among the 5 raters, there was (91.3%) agreement for
AD-like-positive [11C]PiB scans (Fleiss κ = 0.83) and there was
(85.8%) agreement for any-region positive [11C]PiB scans (Fleiss κ =
0.73). In the case of [18F]ﬂutemetamol scans, there was (91.3%) agree-
ment for AD-like-positive (Fleiss κ= 0.83) and (81.7%) agreement for
any-region positive scans (Fleiss κ= 0.63).
Using the consensus rating for the 5 raters for both AD-like and any-
region positivity, there was agreement between the two tracers in
(91.7%, Cohen κ = 0.82) cases for AD-like positivity and in (83.3%,
Cohen κ= 0.67) cases for any-region positivity.3.3. Correlation of rater regional average to global SUVR
Rater regional averages were compared to global SUVR as explained
in Section 2.5.4.3. For [11C]PiB, the correlation coefﬁcient between Glob-
al cortical SUVR and the averaged visual ratings was highly signiﬁcant
[Fig. 4, (R2 = 0.63, P b 0.0001)]. Averaged visual ratings and global cor-
tical SUVR disagreed on their classiﬁcation of two scans, where the
scans were rated as PiB positive quantitatively by global cortical SUVR
but PiB negative by averaged visual classiﬁcation.Fig. 4. Plot of [11C]PiB SUVR vs. visual rating for all subjects. Black triangles indicate a PiB(+)
rating by both SUVR and visual ratings, black circles indicate a PiB(−) rating by both SUVR
and visual ratings. Gray triangles indicate a PiB(+) rating by SUVR and a PiB(−) visual rat-
ing. Points for subjectswith a clinical AD diagnosis are under-struckwith a red box. The line
is the result of a linear regression over all 23 subjects (y= 0.28× + 1.02; R2 = 0.63).
Table 3
Correlation coefﬁcients (R2) of rater regional score to regional SUVR for the Left (L) and
Right (R) posterior cingulate/precuneus (PX), anterior cingulate (AC), frontal cortex
(FR), parietal cortex (PR), lateral temporal cortex (LT).
RPX LPX RAC LAC RFR LFR RPR LPR RLT LLT
PiB 0.669 0.652 0.696 0.676 0.642 0.614 0.444 0.498 0.530 0.511
Flute 0.783 0.705 0.660 0.720 0.736 0.721 0.691 0.658 0.704 0.652
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SUVR and the averaged visual ratings was highly signiﬁcant [Fig. 5,
(R2 = 0.72, P b 0.0001)]. Visual ratings and SUVR disagreed on their
classiﬁcation of four scans, where the scans were rated as positive
quantitatively by global cortical SUVR but negative by averaged visual
classiﬁcation.
3.4. Correlation of rater regional score to regional SUVR
Regional SUVR and rater regional scores were correlated as de-
scribed in Section 2.5.4.4. Correlation coefﬁcients (R2) ranged between
0.44–0.70 for [11C]PiB and 0.65–0.78 for [18F]ﬂutemetamol (Table 3).
3.5. Agreement between visual classiﬁcation and quantitative based
classiﬁcation of amyloid-positivity
Classiﬁcation of amyloid positivity by visual read and by SUVR
is described in Section 2.5.4.5. For [11C]PiB classiﬁcations
disagreed in 2/23 cases (91.3% agreement) with Cohen's
kappa = 0.833. For [18F]ﬂutemetamol classiﬁcations disagreed in 4/23
cases, (82.6% agreement) with a Cohen's kappa = 0.652.
4. Discussion
Both [11C]PiB and [18F]ﬂutemetamol have been shown to robustly
and reliably label brain amyloid plaques (Curtis et al., 2015; Engler
et al., 2004, 2006; Kemppainen et al., 2007; Klunk et al., 2004; Pike
et al., 2007a; Rowe et al., 2007; Wolk et al., 2011). The goal of this
study was to compare the two tracers in the same AD and NC subjects
using both visual reads and SUVR to evaluate amyloid positivity and cor-
relate [11C]PiB and [18F]ﬂutemetamol.
In our study sample, 6 of the15 NL subjects had evidence of amyloid
deposition. It is important to note that in this study, these 6 subjects
were speciﬁcally chosen based on their prior PiB(+) status to assess
the uptake characteristics across a range of amyloid positivity. There-
fore, the proportion of PiB(+) NL subjects in this study (40%) is higher
than some previous reports (Aizenstein et al., 2008; Apostolova et al.,
2010; Furst et al., 2010; Mormino et al., 2009; Pike et al., 2007b; Rentz
et al., 2010; Resnick et al., 2010).
Good correlation was observed between [11C]PiB and
[18F]ﬂutemetamol in SUVR of individual cortical regions and in global
cortical average SUVR (Fig. 3, Table 2). Additionally, we found that there
was also good agreement between the two tracers in classifying
subjects as amyloid-positive.Fig. 5. Plot of [18F]ﬂutemetamol vs. visual rating for all subjects. Black triangles indicate a
Flute(+) rating by both SUVR and visual ratings, black circles indicate a Flute(−) rating by
both SUVR and visual ratings, and gray triangles indicate a Flute(+) rating by SUVR and a
Flute(−) visual rating. Points for subjects with a clinical AD diagnosis are under-struck
with a red box. The line is the result of a linear regression over all 23 subjects (y =
0.31x+ 1.16; R2 = 0.72).However, there were some differences of note between the two ra-
diotracers. As evidenced by the slope of the correlation line in Fig. 3,
the SUVR dynamic range of [18F]ﬂutemetamol is smaller than that of
[11C]PIB. This is not attributable to the denominator of the
(SUVR) ratio, as the average cerebellar cortex reference region
value for [18F]ﬂutemetamol was lower than that for [11C]PiB. Instead,
the lower SUVR range of [18F]ﬂutemetamol likely results from the com-
bination of both higher global region cortical SUV signal in the amyloid-
positive [11C]PIB subjects relative to that for [18F]ﬂutemetamol and the
slightly lower cortical gray matter global region SUV in the amyloid-
negative [11C]PIB subjects relative to that for [18F]ﬂutemetamol as de-
scribed above (i.e., a larger range in the numerator of the ratio for
[11C]PIB).
When examining the agreement across visual raters for both
[11C]PiB and [18F]ﬂutemetamol there was overall good agreement in
rating subjects as AD-like amyloid-positive (Section 3.2). There was,
however, a tendency to assign visual ratings of any-region amyloid
positive to [18F]ﬂutemetamol scans that were, objectively (by SUVR
SKM classiﬁcation, translated from PiB), amyloid negative. This is
thought to reﬂect the inclination to rate higher white matter retention
(see Fig. 2) as cortical [18F]ﬂutemetamol retention. The clinical signiﬁ-
cance of these differences is likely to be more of a concern for individ-
uals with low levels of amyloid deposition or no amyloid deposition
than for those who are clearly positive (i.e. AD-like). This highlights
the critical need for careful training in the visual rating of any amyloid
imaging ligand that exhibits appreciable white matter retention.
There was also a signiﬁcant correlation between visual rating and
the SUVR for both [11C]PiB and [18F]ﬂutemetamol. As Fig. 4 depicts,
there was disagreement between the visual classiﬁcation [PiB(−)]
and the objective SUVR classiﬁcation [PiB(+)] in only two subjects.
The agreement between SUVR classiﬁcation and visual ratings for
amyloid positivity with [18F]ﬂutemetamol was slightly less than
that of [11C]PiB with disagreement between the classiﬁcation for 4
subjects (all objective amyloid-positive and visual amyloid-
negative Fig. 5). In addition, it is interesting to note that for the
most part, when a scan was PiB(+) via SUVR SKM rating, raters
tended to have high conﬁdence (a visual rating score of 4) that the
scan was indeed PiB(+); however, the raters had slightly less conﬁ-
dence with the visual rating for [18F]ﬂutemetamol (i.e. more visual
rating scores between 3 and 4), likely a result of higher white matter
retention in the [18F]ﬂutemetamol images (see Figs. 2, 4 and 5).
The correlations of individual cortical SUVR values to the visual rat-
ing of these individual cortical regions also yielded quite interesting re-
sults. While the correlations between all cortical SUVR values to the
visual rating scores were signiﬁcant for both tracers, the most signiﬁ-
cant correlations were in anterior cingulate and precuneus, which is
noteworthy for two reasons. First, amyloid deposition in both anterior
cingulate and precuneus are very typically observed in AD and an
SKM analysis with regional weighting identiﬁed anterior cingulate and
precuneus as the two regions with the highest weights, meaning that
these regions were most relevant to the analyses. Second, the fact that
both anterior cingulate and precuneus are midline gray matter regions
in which essentially two thicknesses of cortex are adjacent to each
otherwithout interveningwhitemattermay accentuate the appearance
of speciﬁc tracer retention in these areas, particularly in the case of
[18F]ﬂutemetamol.
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There is a high degree of linear correlation between [18F]ﬂutemetamol
and [11C]PiB across all brain regions indicating that both tracers have sim-
ilar retention characteristics. Both tracers performed similarly when a
standardized visual read technique was used to classify scans as
amyloid-positive or amyloid-negative and visual reads correlated well
with SUVR classiﬁcations. However, care in interpretation of amyloid pos-
itive versus amyloid negative regions must be taken, particularly in the
case of [18F]ﬂutemetamol, when considering cortical vs. white-matter
retention.
Acknowledgments
This project is funded, in part, under a grant (ACRIN-PA 4004) with
the Pennsylvania Department of Health to theAmerican College of Radi-
ology Imaging Network (ACRIN). The Department speciﬁcally declaims
responsibility for any analyses, interpretations or conclusions. Addition-
al support, in part, from grants NIH P50 AG005133, P01 AG025204 and
R37 AG025516 is acknowledged.We also greatly appreciate the recruit-
ment efforts of Ms. Claire McConaha.
References
Aizenstein, H.J., Nebes, R.D., Saxton, J.A., Price, J.C., Mathis, C.A., Tsopelas, N.D., Ziolko, S.K.,
Snitz, B.E., Houck, P.R., Bi, W., Cohen, A.D., Lopresti, B.J., DeKosky, S.T., Halligan, E.M.,
Klunk, W.E., 2008. Amyloid deposition is frequent and often is not associated with
signiﬁcant cognitive impairment in the elderly. Arch. Neurol. 65 (11), 1509–1517.
Apostolova, L.G., Hwang, K.S., Andrawis, J.P., Green, A.E., Babakchanian, S., Morra, J.H.,
Cummings, J.L., Toga, A.W., Trojanowski, J.Q., Shaw, L.M., Jack Jr., C.R., Petersen, R.C.,
Aisen, P.S., Jagust, W.J., Koeppe, R.A., Mathis, C.A., Weiner, M.W., Thompson, P.M.,
2010. 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI sub-
jects. Neurobiol. Aging 31 (8), 1284–1303 (PubMed PMID: 20538372).
Cicchetti, D.V., Feinstein, A.R., 1990. High agreement but low kappa: II. Resolving the par-
adoxes. J. Clin. Epidemiol. 43 (6), 551–558.
Cohen, J.A., 1960. A coefﬁcient of agreement for nominal scales. Educ. Psychol. Meas. 20,
37–46.
Cohen, A.D., Mowrey, W., Weissfeld, L.A., Aizenstein, H.J., McDade, E., Mountz, J.M., Nebes,
R.D., Saxton, J.A., Snitz, B., Dekosky, S., Williamson, J., Lopez, O.L., Price, J.C., Mathis,
C.A., Klunk, W.E., 2013. Classiﬁcation of amyloid-positivity in controls: comparison
of visual read and quantitative approaches. Neuroimage. 71, 207–215. http://dx.doi.
org/10.1016/j.neuroimage.2013.01.015 (Epub 2013/01/29, PubMed PMID:
23353602, PubMed Central PMCID: PMC3605888).
Curtis, C., Gamez, J.E., Singh, U., Sadowsky, C.H., Villena, T., Sabbagh, M.N., Beach, T.G.,
Duara, R., Fleisher, A.S., Frey, K.A., Walker, Z., Hunjan, A., Holmes, C., Escovar, Y.M.,
Vera, C.X., Agronin, M.E., Ross, J., Bozoki, A., Akinola, M., Shi, J., Vandenberghe, R.,
Lkonomovic, M.D., Sherwin, P.F., Grachev, I.D., Farrar, G., Smith, A.P.L., Buckley, C.J.,
McLain, R., Salloway, S., 2015. Phase 3 trial of ﬂutemetamol labeled with radioactive
ﬂuorine 18 imaging and neuritic plaque density. JAMA Neurol. 72 (3), 287–294.
http://dx.doi.org/10.1001/jamaneurol.2014.4144 (PubMed PMID: WOS:
000352157200008).
Engler, H., Klunk, W., Nordberg, A., Blomqvist, G., Holt, D., Wang, Y.M., Bergstrom, M.,
Huang, G.F., Estrada, S., Debnath, M., Barletta, J., Sandell, J., Wall, A., Antoni, G.,
Mathis, C., Langstrom, B., 2004. First PET study with a benzothiazol amyloidimaging
agent (PIB) in Alzheimer's disease patients and healthy volunteers. Living Brain
Alzheimers Dis. 123–137 (PubMed PMID: BIOSIS:PREV200510330819).
Engler, H., Forsberg, A., Almkvist, O., Blomquist, G., Larsson, E., Savitcheva, I., Wall, A.,
Ringheim, A., Langstrom, B., Nordberg, A., 2006. Two-year follow-up of amyloid depo-
sition in patients with Alzheimer's disease. Brain 129, 2856–2866 (PubMed PMID:
ISI:000241783800007).
Fleiss, J.L., 1971.Measuring nominal scale agreement amongmany raters. Psychol. Bull. 76
(5), 378–382. http://dx.doi.org/10.1037/h0031619 (PubMed PMID: WOS:
A1971K852700006).
Furst, A.J., Rabinovici, G.D., Rostomian, A.H., Steed, T., Alkalay, A., Racine, C., Miller, B.L.,
Jagust, W.J., 2010. Cognition, glucose metabolism and amyloid burden in Alzheimer's
disease. Neurobiol. Aging 33 (2), 215–225 (PubMed PMID: 20417582).
Head, S.J., Mokhles, M.M., Osnabrugge, R.L., Pibarot, P., Mack, M.J., Takkenberg, J.J., Bogers,
A.J., Kappetein, A.P., 2012. The impact of prosthesis-patient mismatch on long-term
survival after aortic valve replacement: a systematic review and meta-analysis of
34 observational studies comprising 27,186 patients with 133,141 patient-years.
Eur. Heart J. http://dx.doi.org/10.1093/eurheartj/ehs003 (Epub 2012/03/13, PubMed
PMID: 22408037).
Hyman, B.T., Trojanowski, J.Q., 1997. Editorial on consensus recommendations for the
postmortem diagnosis of Alzheimer disease from the National Institute on Aging
and the Reagan Institute working group on diagnostic criteria for the neuropatholog-
ical assessment of Alzheimer disease. J. Neuropathol. Exp. Neurol. 56 (10),
1095–1097 (PubMed PMID: WOS:A1997XZ76300002).Jack, C.R., Bernstein, M.A., Fox, N.C., Thompson, P., Alexander, G., Harvey, D., Borowski, B.,
Britson, P.J., Whitwell, J.L., Ward, C., Dale, A.M., Felmlee, J.P., Gunter, J.L., Hill, D.L.G.,
Killiany, R., Schuff, N., Fox-Bosetti, S., Lin, C., Studholme, C., DeCarli, C.S., Krueger, G.,
Ward, H.A., Metzger, G.J., Scott, K.T., Mallozzi, R., Blezek, D., Levy, J., Debbins, J.P.,
Fleisher, A.S., Albert, M., Green, R., Bartzokis, G., Glover, G., Mugler, J., Weiner, M.W.,
2008. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods.
J. Magn. Reson. Imaging 27 (4), 685–691 (PubMed PMID: WOS:000254709500001).
Kemppainen, N.M., Aalto, S., Wilson, I.A., Nagren, K., Helin, S., Bruck, A., Oikonen, V.,
Kailajarvi, M., Scheinin, M., Viitanen, M., Parkkola, R., Rinne, J.O., 2007. PET amyloid
ligand [C-11]PIB uptake is increased in mild cognitive impairment. Neurology 68
(19), 1603–1606 (PubMed PMID: ISI:000246274600010).
Klunk, W.E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D.P., Bergström, M.,
Savitcheva, I., Huang, G.F., Estrada, S., Ausén, B., Debnath, M.L., Barletta, J., Price, J.C.,
Sandell, J., Lopresti, B.J., Wall, A., Koivisto, P., Antoni, G., Mathis, C.A., Långström, B.,
2004. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B.
Ann. Neurol. 55 (3), 306–319 (PubMed PMID: 14991808).
Mason, N., Klunk, W., Debnath, M., Flatt, N., Huang, G., Shao, L., Mathis, C.A., 2009. Synthe-
sis and evaluation of aromatic: ﬂuorinated F-18 pib analogs as abeta plaque pet im-
aging agents. J. Labelled Compd. Radiopharm. 52, S90-S (PubMed PMID: WOS:
000268724900091).
Mathis, C.A., Wang, Y., Holt, D.P., Huang, G.F., Debnath, M.L., Klunk, W.E., 2003. Synthesis
and evaluation of 11C-labeled 6-substituted 2-aryl benzothiazoles as amyloid imaging
agents. J. Med. Chem. 46, 2740–2754.
Mirra, S.S., Heyman, A., McKeel, D., Sumi, S.M., Crain, B.J., Brownlee, L.M., Vogel, F.S.,
Hughes, J.P., Vanbelle, G., Berg, L., 1991. The consortium to establish a registry for
Alzheimers-disease (Cerad).2. standardization of the neuropathologic assessment of
Alzheimers-disease. Neurology 41 (4), 479–486 (PubMed PMID: WOS:
A1991FG37700002).
Mormino, E.C., Kluth, J.T., Madison, C.M., Rabinovici, G.D., Baker, S.L., Miller, B.L., Koeppe,
R.A., Mathis, C.A., Weiner, M.W., Jagust, W.J., 2009. Episodic memory loss is related
to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 132
(Pt 5), 1310–1323 (PubMed PMID: 19042931).
Pike, K.E., Savage, G., Villemagne, V.L., Ng, S., Moss, S.A., Maruff, P., Mathis, C.A., Klunk,
W.E., Masters, C.L., Rowe, C.C., 2007a. Beta-amyloid imaging and memory in non-
demented individuals: evidence for preclinical Alzheimer's disease. Brain 130,
2837–2844 (PubMed PMID: ISI:000250675200012).
Pike, K.E., Savage, G., Villemagne, V.L., Ng, S., Moss, S.A., Maruff, P., Mathis, C.A., Klunk,
W.E., Masters, C.L., Rowe, C.C., 2007b. β-amyloid imaging and memory in non-
demented individuals: evidence for preclinical Alzheimer's disease. Brain 130 (Pt
11), 2837–2844 (PubMed PMID: 17928318).
Price, J.C., Ziolko, S.K., Weissfeld, L.A., Klunk, W.E., Lopresti, B.J., Hoge, J.A., Lu, X.L., Bi, W.Z.,
Meltzer, C.C., Tsopelas, N., DeKosky, S.T., Mathis, C.A., 2005. FDG and PIBPET imaging
in Alzheimer's disease and mild cognitive impairment. Neuropsychopharmacology
30, S225-S (PubMed PMID: ISI:000233442100583).
Rentz, D.M., Locascio, J.J., Becker, J.A., Moran, E.K., Eng, E., Buckner, R.L., Sperling, R.A.,
Johnson, K.A., 2010. Cognition, reserve, and amyloid deposition in normal aging.
Ann. Neurol. 67 (3), 353–364 (PubMed PMID: 20373347).
Resnick, S.M., Sojkova, J., Zhou, Y., An, Y., Ye, W., Holt, D.P., Dannals, R.F., Mathis, C.A.,
Klunk, W.E., Ferrucci, L., Kraut, M.A., Wong, D.F., 2010. Longitudinal cognitive decline
is associated with ﬁbrillar amyloid-beta measured by [11C]PiB. Neurology 74 (10),
807–815 (PubMed PMID: 20147655).
Rosario, B.L., Weissfeld, L.A., Laymon, C.M., Mathis, C.A., Klunk, W.E., Berginc, M.D., James,
J.A., Hoge, J.A., Price, J.C., 2011. Inter-rater reliability of manual and automated region-
of-interest delineation for PiB PET. Neuroimage 55 (3), 933–941 (PubMed PMID: ISI:
000288313800009).
Rowe, C.C., Ng, S., Ackermann, U., Gong, S.J., Pike, K., Savage, G., Cowie, T.F., Dickinson, K.L.,
Maruff, P., Darby, D., Smith, C., Woodward,M., Merory, J., Tochon-Danguy, H., O'Keefe,
G., Klunk, W.E., Mathis, C.A., Price, J.C., Masters, C.L., Villemagne, V.L., 2007. Imaging
beta-amyloid burden in aging and dementia. Neurology 68 (20), 1718–1725
(PubMed PMID: ISI:000246450500012).
Spitzer, R.L., Fleiss, J.L., 1974. A re-analysis of the reliability of psychiatric diagnosis. Br.
J. Psychiatry 125, 341–372.
Vandenberghe, R., Van Laere, K., Ivanoiu, A., Salmon, E., Bastin, C., Triau, E., Hasselbalch, S.,
Law, I., Andersen, A., Korner, A., Minthon, L., Garraux, G., Nelissen, N., Bormans, G.,
Buckley, C., Owenius, R., Thurfjell, L., Farrar, G., Brooks, D.J., 2010. 18F-ﬂutemetamol
amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2
trial. Ann. Neurol. 68 (3), 319–329. http://dx.doi.org/10.1002/ana.22068 (Epub
2010/08/06, PubMed PMID: 20687209).
Wilson, A.A., Garcia, A., Chestakova, A., Kung, H., Houle, S., 2004. A rapid one-step
radiosynthesis of the beta-amyloid imaging radiotracer N-methyl-C-11 2-(4′-
methylaminophenyl)-6-hydroxybenzothiazole (C-11-6-OH-BTA-1). J. Labelled
Compd. Radiopharm. 47 (10), 679–682. http://dx.doi.org/10.1002/jlcr.854 (PubMed
PMID: WOS:000224594000006).
Wolk, D.A., Grachev, I.D., Buckley, C., Kazi, H., Grady, M.S., Trojanowski, J.Q., Hamilton,
R.H., Sherwin, P., McLain, R., Arnold, S.E., 2011. Association between in vivo ﬂuorine
18-labeled ﬂutemetamol amyloid positron emission tomography imaging and
in vivo cerebral cortical histopathology. Arch. Neurol. 68 (11), 1398–1403. http://
dx.doi.org/10.1001/archneurol.2011.153 (PubMed PMID: WOS:000297014900005).
Woods, R.P., Mazziotta, J.C., Cherry, S.R., 1993. MRI–PET registration with automated
algorithm. J. Comput. Assist. Tomogr. 17 (4), 536–546 (PubMed PMID: WOS:
A1993LM74900004).
